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Abstract
Background: A causal role of the complement system in Alzheimer's disease pathogenesis has
been postulated based on the identification of different activated components up to the membrane
attack complex at amyloid plaques in brain. However, histological studies of amyloid plaque bearing
APP transgenic mice provided only evidence for an activation of the early parts of the complement
cascade. To better understand the contribution of normal aging and amyloid deposition to the
increase in complement activation we performed a detailed characterization of the expression of
the major mouse complement components.
Methods: APP23 mice expressing human APP751 with the Swedish double mutation as well as
C57BL/6 mice were used at different ages. mRNA was quantified by Realtime PCR and the age- as
well as amyloid induced changes determined. The protein levels of complement C1q and C3 were
analysed by Western blotting. Histology was done to test for amyloid plaque association and
activation of the complement cascade.
Results: High mRNA levels were detected for C1q and some inhibitory complement components.
The expression of most activating components starting at C3 was low. Expression of C1q, C3, C4,
C5 and factor B mRNA increased with age in control C57BL/6 mice. C1q and C3 mRNA showed
a substantial additional elevation during amyloid formation in APP23 mice. This increase was
confirmed on the protein level using Western blotting, whereas immunohistology indicated a
recruitment of complement to amyloid plaques up to the C3 convertase.
Conclusion: Early but not late components of the mouse complement system show an age-
dependent increase in expression. The response to amyloid deposition is comparatively smaller.
The low expression of C3 and C5 and failure to upregulate C5 and downstream components differs
from human AD brain and likely contributes to the lack of full complement activation in APP
transgenic mice.
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Background
The complement system is a major effector of the humoral
immune system playing an important role in both innate
and acquired immunogenicity [1]. It consists of various
proteins acting in different but merging cascades, the
main ones being the classical and the alternative pathway.
Most complement protein is synthesized in the liver, but
in brain microglia, astrocytes and also neurons have been
implied in complement synthesis as well [2-4].
A causal role of the complement system in Alzheimer's
disease pathogenesis has been postulated previously (for
a summary see [5-7]). Histological studies of AD brain
detected complement components in association with
parenchymal amyloid plaques but also neurofibrillary
tangles [8]. This includes key components for activation
up to the ultimately formed membrane attack complex [9-
15]. Moreover, an increase in brain complement RNA
expression was described [16]. In biochemical assays,
fibrillar or oligomeric Aβ and aggregated tau have been
demonstrated to activate the classical and alternative com-
plement pathways suggesting an induction of the system
by amyloid deposits in vivo [8,17-20]. Histological stud-
ies of amyloid plaque bearing APP transgenic mice
detected early complement components, whereas down-
stream components forming the membrane attack com-
plex were missing [21]. The first component of the
classical pathway, C1q, could be detected in association
with plaques in an age-dependent manner in APP and
APP/PS1 transgenic mice and was upregulated in plaque-
associated microglia [22]. While it has been argued that
human Aβ may be a poor activator of mouse complement,
humanization of the C1q A chain did not increase activa-
tion] [23,24].
When crossing mice deficient for C1q and APP transgenic
animals, Fonseca and co-workers [25] observed a reduc-
tion in amyloid associated glial and neuritic pathology,
whereas amyloid deposition seemed unaffected. In con-
trast, knock out of C3, at which the classical and alterna-
tive pathways merge, or overexpression of its inhibitor
Crry increased the amyloid load and neurodegeneration
but reduced phagocytic microglia [26,27]. A reduction in
neuritic pathology was also found in APP transgenic mice
lacking clusterin (apolipoprotein J), a regulator of the
complement system [28,29], possibly due to a shift
towards non-fibrillar Aβ deposits. More recently, treat-
ment of APP transgenic mice with a C5a receptor antago-
nist was shown to reduce fibrillar amyloid and gliosis
together with improved synaptophysin staining and
behavioural performance [30]. While these functional
studies suggest a role of complement in amyloid bearing
mouse brain, the partially contrasting effects of C1q and
C3 blockade are remarkable. This may indicate activities
which are independent of full complement activation [7],
in particular since evidence for an activation of down-
stream components is missing. On the other hand, the
incomplete complement activation in APP transgenic
mice raises doubts in the relevance of the neuroprotective
effects for human AD brain. Although the mentioned data
overall suggest a deleterious role, the significance of com-
plement activation in AD brain remains unclear at
present.
To better understand the age- and amyloid-related
changes in the complement profile of mouse brain we
have analyzed the expression of the major components
during aging of C57BL/6 mice as well as during amyloid
deposition in the APP transgenic mouse line APP23.
Methods
APP23 mice overexpressing human APP751 with the
Swedish double mutation [31] as well as C57BL/6 (non-
transgenic littermates) and BUB/BnJ [32] mice were ana-
lyzed at the age of 3-30 months. mRNA was quantified by
Realtime PCR [33], proteins were analyzed by Western
blotting and histology. For comparison of expression lev-
els human samples were analyzed likewise. The human
samples were obtained from the Institute of Pathology,
University of Basel, Switzerland as approved by the ethics
commission of Basel.
Animals
Female APP23 mice (B6, D2-Tg(Thy1App)23/1Sdz) and
non transgenic littermates at 3, 6, 9, 12, 15, 18, 24 and 30
months were obtained from Novartis Pharma AG, Special
Breeding, Basel, St. Johann, Switzerland. BUB/BnJ mice at
2 months were obtained from Jackson Laboratories, Bar
Harbor, USA. Mice were kept under standard conditions.
The study was done under animal permission No. 1795 as
issued by the Kantonales Veterinäramt Basel-Stadt.
Forebrain, brain, liver and serum preparation
For forebrain and serum preparation the animals were
anaesthetized with 3.5% (volume) isoflurane (FORENE;
Abott Laboratories, #B506) in a narcotic chamber and
decapitated immediately. The blood was collected in
microtainers (BD Bioscience, #365951) and used to pre-
pare serum samples. Blood samples were kept at RT for 30
min, centrifuged (4°C, 6800 g, 15 min) to obtain the sera
and stored at -80°C until they were used for Western
blots. The brains were removed and separated into left
and right hemisphere. Forebrains were separated from cer-
ebellum and brain stem and immediately frozen on a
metal plate on dry ice. From some animals the liver was
removed and frozen in the same way. Samples were stored
at -80°C until use for RNA isolation or Western blots.
The frontal cortex region (F2) was obtained at autopsy
from 3 individuals without a history of neurological dis-Journal of Neuroinflammation 2009, 6:35 http://www.jneuroinflammation.com/content/6/1/35
Page 3 of 12
(page number not for citation purposes)
ease and AD pathology (1 female and 2 males; age 61 - 78
years; post mortem delay 3.5 - 12 hours). The tissues were
frozen at -80°C until use.
PBS perfusion of mice
Pentobarbital anaesthetized (50 mg/ml Nembutal;
Abbott Laboratories, #6900) mice were perfused transcar-
dially with 0.01 M PBS pH 7.4 (Sigma, #P-4417) for about
8 minutes at room temperature. Brains were removed
from skull, separated into left and right hemisphere, sep-
arated from cerebellum and brain stem, immediately fro-
zen on a metal plate on dry ice and kept at -80°C until
use.
Total RNA extraction and cDNA synthesis
For total RNA extraction from frozen forebrains the RNe-
asy Lipid Tissue Mini Kit from QIAGEN (#74804) was
used according to the manufacturer's instructions. The tis-
sue was homogenized in the Retsch Mill MM 300 (QIA-
GEN, #85120) for 2 min at 20 Hz followed by 1 min at 30
Hz. During the RNA extraction procedure the optional
DNase treatment was carried out with the RNase-free
DNase Set (QIAGEN, #79254) as described by the manu-
facturer. After extraction the concentration and purity of
the RNA was determined by spectrophotometry (absorp-
tion at 260 nm and 280 nm). mRNA was reverse tran-
scribed into cDNA using the ABI High Capacity cDNA
Archive Kit (Applied Biosystems, #4322171). For total
RNA extraction from mouse liver the RNeasy Mini Kit
(QIAGEN, #74104) was used. Homogenization, DNase
treatment and cDNA synthesis was done as described
above. For RNA extraction from human brain/liver and
cDNA synthesis the same procedures were used. Addition-
ally two human RNAs from liver were ordered at Ambion
(#7960) and Stratagene (#540017).
Realtime-PCR gene expression analysis
Gene expression analysis was done by Realtime-PCR on
an ABI PRISM 7700 Sequence Detection System (Applied
Biosystems) [33]. TaqMan Gene Expression Assays were
ordered from Applied Biosystems and Eurogentec or
designed by us (see additional file 1: Assays used to quan-
tify the expression of different complement components
by Realtime-PCR in mice; and additional file 2: Assays
used to quantify the expression of different complement
components by Realtime-PCR in humans). The same
cycle thresholds (Ct) were set for the different assays.
Amplification was carried out with the qPCR MasterMix
from Eurogentec (#RT-QP2X-03).
Quantification was done using the comparative Ct
method (User Bulletin #2 ABI PRISM 7700 Sequence
Detection System, Applied Biosystems), i.e. expression
levels for the target genes were normalized to the 18srRNA
of each sample [2-ΔCt = 2-(Ct(target gene)-(Ct(18srRNA))]. Addi-
tionally two other housekeeping genes, HPRT and
GAPDH, were analyzed to confirm the results as well as
the integrity and quality of the cDNA (data not shown).
Realtime-PCR quantifications were run in triplicate for
each sample and the average determined. Mice were ana-
lyzed in groups of 8-12 per genotype. Human samples
were analyzed likewise. Liver samples were used as posi-
tive control for all complement mRNA assays. In order to
use the comparative Ct method for relative quantification
the amplification efficiency of target and housekeeping
gene must be approximately equal. All TaqMan Gene
Expression Assays are optimized to 100% efficiency (+/-
10%) [34]. Self-designed primers and probes were ana-
lyzed for amplification efficiency using the Ct slope
method. For this method a 6-log dilution range of target
template was generated using 10-fold dilutions and the Ct
value was determined. A plot of Ct versus log cDNA con-
centration was constructed. The optimal slope for this
dilution series is -3.32 which results in a 100% amplifica-
tion efficiency (Ex = 1.0). A similar efficiency as for the
TaqMan assays was obtained (data not shown).
Western blot analysis
For Western blot analysis forebrains were homogenized in
the Retsch Mill MM 300 followed by brief sonication to
obtain a 1:10 dilution of forebrain homogenate in TBS
complete (137 mM NaCl; 20 mM Tris/HCl pH 7.6; 1×
complete (protease inhibitor cocktail tablet, Roche,
#11836145001)). For gel electrophoresis an aliquot of
forebrain homogenate or serum was diluted in SDS sam-
ple buffer. Proteins were separated by 8%, 12% and/or
15% SDS-PAGE (ratio of acrylamid/bisacrylamide 29:1)
under reducing or non-reducing conditions (see addi-
tional file 3: Complement antibodies used on Western
blots). They were transferred to polyvinylidene difluoride
(PVDF) membranes (Millipore, #IPVH00010) by semi-
dry blot. Membranes were blocked with 2% ECL Advance
blocking agent (Amersham, #RPN2135) in PBST (Sigma,
#P-3563). Antibodies were diluted in blocking solution
and incubated for 1 h at room temperature or over night
at 4°C. Detection of bound antibodies was carried out
with peroxidase coupled secondary antibodies using the
ECL Western blotting Detection system (Amersham,
#RPN2106) or the ECL Advance Western blotting Detec-
tion System (Amersham, #RPN2135). For C1q and C3a
detection the samples were analyzed under reducing con-
ditions (with β-mercaptoethanol). For C3 analysis both
conditions, reducing and non-reducing, were used. For
quantification of C1q, different amounts of purified
human protein (Calbiochem, #204876) were loaded on
each gel along with the samples to be analyzed. The bands
obtained on X-ray films were quantified using the pro-
gram MCID Elite 7.0 (Imaging Research Inc.). Protein lev-
els were read from standard curves generated with the
Origin 7.5 software (OriginLab Corporation) by logisticJournal of Neuroinflammation 2009, 6:35 http://www.jneuroinflammation.com/content/6/1/35
Page 4 of 12
(page number not for citation purposes)
curve fitting. The concentrations were expressed per
weight of forebrain relative to the control group. A mouse
C1q standard was not available and the potential differ-
ence in antibody affinity does not allow determination of
absolute values. For quantification of C3 the purified
human protein could not be used as a standard due to the
species specificity of the antibody. An antibody recogniz-
ing both mouse and human C3 on Western blots was not
available. Therefore the concentrations were expressed in
arbitrary units.
Immunoprecipitation (IP) of C3a from forebrain
For IP of C3a human brain samples and mouse forebrains
were homogenized as described above to obtain 1:10
dilutions in TBS complete. To generate standard curves
different amounts of purified human C3a protein (Cortex
Biochem #CP1039) were added to non-transgenic fore-
brain homogenates for extraction and IP. Aliquots of 100
μl were used. After addition of NP40 (final concentration
0.1%) all samples were vortexed and incubated on ice for
15 minutes. During incubation they were mixed every 5
minutes. After centrifugation (15 minutes, 4°C, 20000 g)
the cleared supernatant was transferred to a fresh tube and
used for IP. IP was carried out using Dynabeads Protein G
(Dynal, #100.03). For each sample 10 μl beads were used.
Beads were resuspended by thoroughly vortexing and
washed twice in 0.1 M Na-phosphate buffer, pH 5.8 using
the Dynal MPC-S magnet (Dynal, #120.20). Finally the
beads were resuspended in the original volume. For each
10 μl beads 5 μl of the C3a antibody was added to the pre-
washed beads, mixed and preincubated for at least 2
hours on a vertical end-over-end rotator. After preincuba-
tion the beads were washed again in 0.1 M Na-phosphate
buffer pH 5.8 and then resuspended in the original vol-
ume. For IP 10 μl of washed antibody bound beads were
added to the prepared samples and incubated over night
at 4°C on a vertical end-over-end rotator. After incubation
vials were placed on the magnet, the supernatant was
removed and the beads were washed in 1% NP40 in TBS
complete followed by 10 mM Tris (pH 7.5) and 1 mM Tris
(pH 7.5). After each washing step the supernatant was
removed on the magnet. Following the last washing step
the samples were briefly spun down and the remaining
supernatant was collected on the magnet. Finally the
beads were resuspended in 10 μl 1.3× Laemmli sample
buffer for Western blot analysis.
Histology
Immersion fixed brains from APP23 mice at 20 months of
age and pieces from the frontal pole (F2) of two AD brains
(1st: male, aged 74, CERAD C, Braak IV; 2nd: female, aged
82, CERAD C, Braak V) were embedded into paraffin and
cut with a microtome into sections of 4 μm. Sections were
deparaffinized in xylene and rehydrated in a descending
concentration of ethanol in H2O. Antigenity was
enhanced by microwave heating of sections in 0.1 M citric
acid buffer at 90°C for 60 minutes. Tyramide Signal
Amplification (TSA plus) immuno fluorescence histo-
chemistry was performed using a commercial kit (TSA-
direct kit, NEN Life Science, Perkin Elmer). Different anti-
bodies were tested to localize complement components in
brain (see additional file 4: Complement antibodies used
in histology). Sections were incubated for 24 h at 4°C
with primary antisera/antibodies, diluted in TNT (0.3%
Triton X-100, 100 mM Tris, 150 mM NaCl). Negative con-
trols included omission of the primary antisera and sub-
stitution by different non-immune sera. After incubation
the sections were rinsed in TNT (6 × 5 min) and incubated
at RT for 1 h in secondary antibody solution. The horse-
radish peroxidase (HPR, DAKO) labelled secondary anti-
body was diluted 1:200 in TNB (0.5% blocking solution
TSA Kit NEL 741). After 6 × 5 min TNT washing sections
were incubated for 15 min in FITC-Tyramide solution
(1:200 dilution in amplification buffer according manu-
factures conditions). After washing in TNT and transfer-
ring to Super Frost Plus glass slides (Menzel, Heidelberg)
sections were embedded in Vectashield (Vector, H-1000)
for Fluorescence microscopy. Sections were examined and
photographed using fluorescence microscopy with the
following filter combination: excitation 450-490 nm,
emission 510 nm.
Statistical analysis
The averages were calculated for all groups as the data
were normally distributed for most of the groups. Calcu-
lation of medians gave very similar results. At each age the
transgenic group was compared to the corresponding
wildtype control group, i.e. pair wise comparison to the
control group was done using 2-tailed Student's t-test (p <
0.05 considered significant). In the kinetic analyses we
compared the transgenic and non-transgenic groups at
each age using 2-tailed Student's t-test. In addition for
both genotypes each age was compared to the correspond-
ing 3 months group using Dunnetts test.
Results
mRNA expression of complement components in amyloid 
plaque-containing APP23 and control mouse brain
APP23 mice show an age-related increase in amyloid
plaque deposition as well as in plaque-associated altera-
tions such as gliosis. We, therefore, initially compared 24
months old female APP23 with age-matched non-trans-
genic mice to identify alterations in expression of key
complement components in forebrain by Realtime-PCR.
The values given for all complement mRNAs are normal-
ized to 18srRNA; very similar results were obtained by
normalization to the housekeeping genes HPRT or
GAPDH.Journal of Neuroinflammation 2009, 6:35 http://www.jneuroinflammation.com/content/6/1/35
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The mRNAs of only some complement components were
substantially and significantly elevated relative to non-
transgenic mice. These include the initiator of the classical
pathway C1q, the central component C3, which also ini-
tiates the alternative pathway, and an alternative pathway
inhibitor, factor H. The increase of factor B, a specific
member of the alternative pathway, just did not reach sig-
nificance (Table 1). Other components, C4, C5 and the
inhibitor Crry, were unchanged. Only components of the
early complement activation steps were increased.
The levels of the complement mRNAs seemed to differ
considerably for the different components (Table 1).
Although a direct comparison of the units determined is
not possible, all assays were shown to have similar effi-
ciencies (see methods) and it appears unlikely that sys-
tematic differences of about an order of magnitude are
due to assay differences. The highest levels were found for
both components of the classical complement pathway,
C1q and C4, while far lower values were determined for
factor B, representing the alternative pathway. C3 showed
a relatively strong expression, but the precursor of the sec-
ond convertase C5 was much less expressed. The RNAs of
terminal sequence components C6 and C8b could be
measured but were below the limit of quantification. C8a
and C9 mRNA remained below the limit of detection in
control and APP23 mice. The inhibitory complement
components factor H and Crry were remarkably well
expressed. In comparison, MCP RNA was low, which may
be due to the fact that in mice the function of MCP is
mainly carried out by Crry [35,36].
We also analyzed a group of perfused 25 months old
APP23 mice to test if the blood remaining in brain might
influence the results. Very similar expression levels were
found for C1q, C3, C4, C5 and factor B mRNA (data not
shown).
Age-dependent complement expression in non-transgenic 
mouse brain
To evaluate changes in complement expression with nor-
mal aging we determined the mRNA levels of all studied
components in young non-transgenic mice (3 months of
age). Comparison with the expression levels in 24 months
old mice showed a substantial increase with age for C3
and C4, while C1q, factor B and C5 were elevated to a
smaller degree (Table 2). The later components of the ter-
minal sequence showed very low if any expression in
young as well as old animals. The inhibitory factors tested
also did not seem to change much with age. We also ana-
Table 1: Brain mRNA expression of complement components in APP23 and non-transgenic controls at 24 months
pathway/function control mice ± SEM APP23 ± SEM p (2 tailed t-test) increase APP23
C1q classical pathway 89'040 ± 4'788 189'896 ± 7'721 0.000000006 2×
C4 classical pathway 10'042 ± 1'104 11'016 ± 1'754 0.64 1×
factor B alternative pathway 647 ± 92 1'029 ± 164 0.06 1.6×
C3 all pathways 3'317 ± 114 10'550 ± 1'507 0.0007 3
C5 terminal sequence 117 ± 11 128 ± 12 0.51 1×
C6 terminal sequence 13
(below limit of quantification)
43
(below limit of quantification)
--
C8a terminal sequence not detectable not detectable - -
C8b terminal sequence 32
(below limit of quantification)
46
(below limit of quantification)
--
C9 terminal sequence not detectable not detectable - -
Crry inhibitor all pathways 48'546 ± 4'156 49'891 ± 3'120 0.80 1×
MCP inhibitor all pathways 20
(below limit of quantification)
37
(below limit of quantification)
--
factor H inhibitor alternative pathway 14'756 ± 723 21'509 ± 913 0.00001 1.5×
Values are given as arbitrary units.Journal of Neuroinflammation 2009, 6:35 http://www.jneuroinflammation.com/content/6/1/35
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lyzed APP23 mice at 3 months of age and found no differ-
ence in expression compared to non-transgenic animals
(data not shown). An exception was C4 as its expression
was lower in young APP23 than in non-transgenic mice
(see below).
Very low complement activity has been claimed for stand-
ard laboratory mouse strains including C57BL/6, the
background strain of APP23, while much higher activity
was found in BUB/BnJ mice [32,37]. To test if this strain
might provide a background more favourable for comple-
ment activation we determined the expression of C1q, C3,
C5, C6 and C9 in forebrain of male BUB/BnJ mice but
found no major differences compared to C57BL/6 (data
not shown).
Complement mRNA expression in mouse liver
Liver is the main source of the complement components
in the body and we determined the expression of the most
important factors in order to compare with brain (see
additional file 5: Expression of complement components
in the liver of APP23 mice). All components were
expressed well in liver including C9, which was easily
detected. Except for C1q, which showed the same expres-
sion as in brain, all other components reached much
higher mRNA levels in the liver. Consequently, the ratio
between the different complement mRNAs was very dif-
ferent in brain and liver.
Complement mRNA expression in human brain and liver
Complement factors up to C9 have been found in human
brain [2-4]. We analyzed cerebral cortex from 3 aged but
non-demented donors for complement expression (see
additional file 6: Complement mRNA expression in
human cerebral cortex and liver). C1q mRNA levels were
in the range of those found in mice. In contrast, C3 and
C5 showed considerably higher levels in human brain.
Similar to mouse brain, C6 expression was low and C9
expression was not detectable in human brain. The
mRNAs of the inhibitory components factor H and MCP
were in the range of mouse brain considering that Crry
and MCP are functional homologs. Similar to mouse,
human liver showed high expression of all tested comple-
ment components.
Brain C1q, C3, C4 and factor H and B mRNA expression 
during aging and amyloid deposition
The main complement components with altered brain
expression in old APP23 mice were C1q, C3, factor H and
possibly factor B, whereas C4 seemed reduced in young
transgenic animals. The expression kinetics of these com-
ponents were analyzed in forebrain of female APP23 and
Table 2: Age dependent increase of complement expression in non-transgenic mouse brain
3 months SEM 24 months SEM p (2 tailed t-test) increase with age
C1q 28'345 2'339 89'040 4'788 0.0000001 3×
C4 1'113 155 10'042 1'104 0.00003 9×
factor B 224 28 647 92 0.0009 3×
C3 349 38 3'317 114 0.0000000004 9×
C5 68 7 117 11 0.00001 2×
C6 6 - 13 - - below limit of quantification
C8a not detectable - not detectable - - -
C8b 41 - 32 - - below limit of quantification
C9 not detectable - not detectable - - -
Crry 39'007 1'672 48'546 4'156 0.05 1×
MCP 15 3 20 2 - below limit of quantification
factor H 16'861 1'532 14'756 723 0.24 1×
Values are given as arbitrary units.Journal of Neuroinflammation 2009, 6:35 http://www.jneuroinflammation.com/content/6/1/35
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control mice at 3, 6, 9, 12, 15, 18, 24 and 30 months using
Realtime-PCR.
C1q expression remained similar in APP23 and non-
transgenic mice at 3 and 6 months (Figure 1A). An
increase over age-matched controls was detectable at 9
months when the first amyloid deposits had formed. This
increase became larger during further aging reaching a fac-
tor of ~2, which was not exceeded much even at 30
months of age. However, compared to baseline at 3
months C1q expression in APP23 mice had increased 14-
fold at 30 months. Non-transgenic mice also showed a
considerable elevation of C1q expression during aging (7-
fold at 30 months). The age-related elevation in non-
transgenics explains the relatively small increase when
APP23 mice are compared to age-matched controls.
During aging C3 increased in non-transgenic mice (~56-
fold at 30 months compared to 3 months) and much
stronger in APP23 mice (~140-fold) (Figure 1B). No dif-
ference between APP23 and non-transgenic mice was
detectable for C3 until 15 months of age. Compared to
age-matched controls an elevation of ~3-fold was reached
at 24 and remained at 30 months of age. This elevation
started much later than for C1q. It matched in time with
the small increase over age-matched controls of factors B
and H, a component and an inhibitor, respectively, of C3
convertase in the alternative pathway. For factor B the ele-
vation over non-transgenic mice started at 18 months
(1.5-fold) but was small (24 months: 1.6-fold, 30
months: 1.3-fold) (Figure 1C). Compared to 3 months
factor B expression also increased during aging in both
APP23 and control mice. Factor H expression as well was
first elevated in APP23 mice compared to age matched
controls at 18 months reaching an about 1.5-fold increase
at 24 months of age (data not shown). Non-transgenic
mice did not show a consistent age-related expression
change.
A brain expression increase with age was also found for C4
in APP23 (~34-fold) and control (~20-fold) mice (signif-
icant from 24 months on, (Figure 1D)). However, APP23
started at a significantly lower expression level (0.5-fold)
than non-transgenic controls. This difference was lost at
Brain C1q, C3, factor B, C4 expression during aging in APP23 and control mice Figure 1
Brain C1q, C3, factor B, C4 expression during aging in APP23 and control mice. Pair-wise comparison of transgenic 
and non-transgenic groups at each age using the 2-tailed t-test (* p = 0.05-0.01; ** p = 0.01-0.001; *** p = < 0.001); A: C1q 
expression (comparison of 3 months group with aged groups using Dunnetts test showed significance (p < 0.05) from 15 
months (APP23) and 18 months (controls) onwards); B: C3 expression (comparison of 3 months group with aged groups 
showed significance from 24 months onwards (APP23 and controls)); C: factor B expression (comparison of 3 months group 
with aged groups showed significance from 18 months (APP23) and 24 months (controls) onwards); D: C4 expression (com-
parison of 3 months group with aged groups showed significance from 24 months onwards (APP23 and controls)).
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15 months indicating a transgene-induced elevation of
expression, which adds to the age-related increase in non-
transgenic mice. The reason for the lower C4 mRNA
expression in young APP23 transgenic mice remains
unclear.
Complement C1q and C3 protein in brain of aging APP23 
and control mice
We next attempted to detect the complement proteins in
mouse brain homogenates to confirm the increases found
on the RNA level. Among several antibodies tested, suited
ones reacting with mouse complement components on
Western blots were only found for C1q, C3 and C3a.
In mouse brain the C1q antibody specifically detected one
band at 26 kDa corresponding to the C1q B chain (Figure
2A). It did not react well with chain A and C. In control
mice (C57BL/6) the C1q band increased with age. Aged
APP23 showed an additional elevation over age-matched
controls. There was no difference in the intensity of the
C1q signals between PBS perfused and non-perfused fore-
brains indicating little contribution from blood. To quan-
tify the increase in C1q expression on the protein level,
groups of APP23 (n = 8) and control forebrains (n = 8) at
3, 6, 15 and 24 months were analyzed by Western blot-
ting. The C1q B chain at 26 kDa was quantified using the
corresponding band from purified human C1q as stand-
ard (Figure 2B, see also methods). Brain C1q in C57BL/6
mice remained constant between 3 and 6 months but
showed an age-dependent increase starting at 15 months
reaching significance at 24 months. At 3 months of age no
difference in the C1q forebrain concentration could be
detected between APP23 and control mice. There was a
small just significant reduction of C1q in the APP23 group
at 6 months of age which failed to reach significance in a
second quantification. At 15 months APP23 mice showed
a non-significant C1q elevation of 31%, which rose to a
significant increase of 181% at 24 months. These results
are in good agreement with the data found on the mRNA
level.
C3 could be detected in forebrain, serum and liver of con-
trol mice and was notably increased in brain of 24 months
old APP23 compared to age matched controls. After PBS
perfusion of the mice the intensity of the C3 band
decreased both in APP23 and control mice which indi-
cated that part of the C3 signal in non-perfused forebrains
originated from the remaining blood (Figure 3A). In con-
trast to C1q, where residual blood could be neglected (see
above), C3 reaches a lower concentration in brain but a
higher one in plasma resulting in detectable contamina-
tion of non-perfused brain samples. To estimate the
change in C3, groups (n = 9) of PBS-perfused APP23 and
non-transgenic forebrains at 25 months of age were ana-
lyzed by Western blotting. In APP23 mice C3 was
increased almost 4 fold compared to controls (Figure 3B).
This was in good agreement with the mRNA quantifica-
tion results.
The major complement amplification step includes C3
cleavage generating C3a and C3b. To obtain evidence for
this activation we attempted to immunoprecipitate C3a
followed by Western blot detection. Purified human C3a
protein was recognized by a rabbit anti-human C3a anti-
body at 9 kDa. This antibody also reacted with a distinc-
tive band in human brain and serum as well as in APP23
and control serum. In perfused APP23 forebrain, how-
ever, no specific band could be detected.
Immunohistochemical localization of complement 
components in APP23 and AD brain
Using the highly sensitive TSA detection method immu-
nohistochemical staining of Alzheimer brain tissue was
obtained with antibodies to proteins associated with the
classical complement pathway (Clq, C3, C3d) and the ter-
minal sequence (C7 and C9) (Figure 4A). These antibod-
Age dependency of C1q protein levels in APP23 and control  mouse forebrain Figure 2
Age dependency of C1q protein levels in APP23 and 
control mouse forebrain. A: Representative Western 
blot of APP23 and control forebrain at different ages as well 
as purified human C1q protein standards. Proteins were sep-
arated by 12% SDS-PAGE under reducing conditions, 
detected with a goat C1q antibody (Calbiochem): B: Quanti-
fication of C1q from Western blot analysis of APP23 and 
control forebrain at different ages (n = 8). Transgenic and 
non-transgenic groups were compared at each age using the 
2-tailed t-test (* p = 0.05-0.01; ** p = 0.01-0.001; *** p = < 
0.001); comparison of the 3 months groups (APP23 and con-
trols) with aged groups using Dunnetts test showed signifi-
cant increases (p < 0.05) at 24 months.
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ies stained senile plaques, dystrophic neurites and some
neurofibrillary tangles as previously described [21]. The
C7 antibody showed rather weak staining of some amy-
loid plaque cores only. In contrast, C9 labelling of plaques
and tangles was relatively strong, which has been taken as
evidence of a full activation of the complement cascade in
human brain [13,21].
In APP23 mice complement proteins C1q, C3 and C3d
were found strongly associated with compact amyloid
deposits (Figure 4B). C3d staining demonstrated some
activation of the key amplification step. As compared to
humans the recruitment of early complement compo-
nents was similar. Unlike human AD brain C7 was absent
from the amyloid plaque core but could be detected as
weak staining in the plaque periphery, which likely
reflects an association with cellular elements. C9
remained very weak or negative. Although the antibody
recognized murine C9 on Western blots of serum a
reduced reactivity on mouse brain as compared to human
histological sections cannot be excluded. Non-transgenic
mice did not show any specific staining.
Discussion
Considerable histological evidence has been obtained
indicating a full activation of the complement cascade up
to the membrane attack complex in human AD brain. In
contrast, decoration of amyloid plaques in APP transgenic
mouse models has been limited to early components. To
better understand the contribution of age and amyloid
deposition, we have analyzed the expression of comple-
ment components during aging and their induction by
amyloid deposition in brain of wildtype and plaque-
forming APP transgenic mice.
Expression of early complement components was detect-
able already in young C57BL/6 wildtype animals. During
aging, in particular after 15 months, the levels increased
considerably but disproportionate thus changing the ratio
between the different mRNAs (C5: 2×, C1q and factor B:
3×, C3 and C4: 9× between 3 and 24 months). Our data
demonstrate an age-related increase in RNA expression for
both, the classical and alternative complement pathways.
In pre-plaque APP23 mice, complement expression did
not differ from the C57BL/6 controls an exception being a
reduction in C4. At 24 months some of the complement
RNAs were elevated beyond the aged control mice (factor
B: 1.5×, C1q: 2×, C3: 3×), while C4 now reached wildtype
levels. The transgene-related increases were generally
smaller than the age-related elevations. These data are
consistent with the increased C3 expression described in
the J20 APP transgenic mouse line [27]. Interestingly, in a
C3 protein in perfused and non-perfused APP23 and control forebrain Figure 3
C3 protein in perfused and non-perfused APP23 and control forebrain. A: Western blot analysis of APP23 and con-
trol forebrain at 24 months of age (PBS-perfused and non-perfused). Proteins were separated by 8% SDS-PAGE under non-
reducing conditions and detected with a goat anti-C3 antibody (Cappel); B: Quantification of C3 in PBS-perfused forebrains of 
APP23 and control mice at 24 months of age.
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mouse model for cerebral microvascular Aβ deposition
C1q, C3 and C4 have also been found elevated [38]. The
kinetics of complement RNA induction were very similar
for APP23 and C57BL/6 mice. The earliest mRNA increase
was found for C1q at 9 months of age. A significant eleva-
tion of C4 mRNA could only be detected at 15 months fol-
lowed by C3 and factor B RNAs at 18 months.
Quantification of C1q and C3 polypeptides demonstrated
similar increases thus confirming the changes of the major
factors on the protein level. These data show that the ele-
vation of early complement expression in mouse brain is
primarily age-related with only a smaller additional
response to amyloid deposition. The known increase and
activation of glia during amyloid deposition in APP23
mice [39] may contribute to this further elevation. Inter-
estingly, neither the age- nor the amyloid-related increase
reached a plateau as may be expected. This could be
related to the lack of full complement activation in con-
junction with missing negative feedback.
In contrast to the early complement components, brain
mRNA levels of the final ones following C5 were very low
or not detectable and remained unchanged during aging
of both, C57BL/6 and APP23 mice. Among all activating
complement components analyzed, only C1q expression
reached levels comparable to liver, whereas the others
remained considerably lower. The BUB/BnJ mouse strain,
claimed to show higher complement activity than the
C57BL/6 strain used here [32,37], did not differ in brain
complement expression. This is in line with the recent
demonstration of a similar serum complement activity as
other mouse strains [40]. This strain, therefore, does not
seem suited to promote brain expression of the final com-
plement components.
Our preliminary analysis of a small number of aged
human brain samples also indicates a reduced expression
towards the later complement components including a
lack of detectable C9 mRNA. However, the human brain
expression levels in particular of C3 and C5 were consid-
erably higher than mouse brain expression. Previous stud-
ies moreover indicated a substantial mRNA up-regulation
for all classical and the alternative pathway component
factor B in AD brain [16,41]. This increase in expression of
components required to activate complement is in clear
contrast to our observations in APP transgenic mice,
where complement mRNA upregulation is restricted to
early components.
Interestingly, high mouse brain expression was found for
the inhibitors Crry and factor H, which block formation of
the C3 convertase. The levels were similar in wildtype and
APP23 transgenic mice, remained stable throughout aging
and were comparable to human brain considering MPC as
the functional Crry analog. Irrespective of these high
inhibitor levels some C3 convertase activation still seems
to occur. Otherwise overexpression of soluble Crry and
deletion of C3, which increased Aβ deposition and neuro-
degeneration [26,27], should not have led to any changes.
Similarly, the beneficial effect of the C5aR antagonist on
the APP transgenic mouse pathology [30] can only be
observed in the presence of some C5 activation. However,
Complement immunostaining of AD and APP23 mouse brain Figure 4
Complement immunostaining of AD and APP23 
mouse brain. A: Neocortex (F2) of an AD brain: C1q, C3, 
C3d, C7 and C9 immunostaining of diffuse (red arrow), com-
pact (violet arrow) and cored (blue arrow) amyloid plaques 
and neurofibrillary tangles (yellow arrow); bar = 50 μm; B: 
Neocortex of a 20 months old female APP23 mouse: C1q, 
C3 and C3d immunostaining of diffuse (red arrow) and com-
pact (violet arrow) amyloid plaques; C7 immunostaining of 
the amyloid plaque periphery (yellow arrow); C9 staining: 
weak fluorescence above background (control), no specific 
staining of non-transgenic mice (control); bar = 100 μm.
A
AD ± C3 AD ± C3d AD ± C1q
AD ± C7 AD ± C9 AD ± C9
B
APP23 ± C3d APP23 ± C3 APP23 ± C1q
control ± C7 APP23 ± C7
control ± C9 APP23 ± C9Journal of Neuroinflammation 2009, 6:35 http://www.jneuroinflammation.com/content/6/1/35
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interference at C3 and C5 in humans may have a different
outcome than in mice owing to the different expression
levels and activator/inhibitor ratios.
Using AD brain sections we could easily detect C1q, C3,
C3d, C7 and C9 at amyloid plaques and neurofibrillary
tangles confirming previous data [10,13-15,20,21]. Simi-
lar staining of the early complement components C1q, C3
and C3d was found in aged APP23 mouse brain. This is at
variance from Schwab and co-workers [21] who described
a general decrease in complement protein staining in
APP23 mice. The difference may be explained by a lower
reactivity of their antibodies with the mouse proteins. The
generation of C3d indicates some activation of C3 conver-
tase. Nonetheless, the downstream component C7 was
not associated with the amyloid plaque center but weakly
detected in the periphery, likely in cellular elements. Con-
sequently, C9 staining could not be found in APP23 mice.
This lack of plaque decoration by the downstream com-
plement components contrasts the human situation and
argues against a comparable activation.
Conclusion
Overall, our data indicate a low complement expression
in mice from the C3 component onwards. Starting at C5
the mRNAs did not increase in response to amyloid dep-
osition, which is in contrast to human brain. While we
have not detected a clear immunohistological difference
to human AD brain at the C3 level, the reduced expression
matches with the lack of deposition of the downstream
components on amyloid plaques in mice. The low expres-
sion may hence contribute to the restricted complement
activation but it is not restricted to the loss of a specific
component.
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